181 related articles for article (PubMed ID: 32994431)
1. Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.
Harms M; Gilg A; Ständker L; Beer AJ; Mayer B; Rasche V; Gruber CW; Münch J
Sci Rep; 2020 Sep; 10(1):16036. PubMed ID: 32994431
[TBL] [Abstract][Full Text] [Related]
2. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.
Schoofs G; Van Hout A; D'huys T; Schols D; Van Loy T
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29578516
[TBL] [Abstract][Full Text] [Related]
3. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
Zhao Q; Lu H; Schols D; De Clercq E; Jiang S
AIDS Res Hum Retroviruses; 2003 Nov; 19(11):947-55. PubMed ID: 14678601
[TBL] [Abstract][Full Text] [Related]
4. A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics.
Costa MJ; Kudaravalli J; Liu WH; Stock J; Kong S; Liu SH
PLoS One; 2018; 13(3):e0194688. PubMed ID: 29554149
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.
Sakyiamah MM; Kobayakawa T; Fujino M; Konno M; Narumi T; Tanaka T; Nomura W; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2019 Mar; 27(6):1130-1138. PubMed ID: 30772128
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.
Li Z; Wang X; Lin Y; Wang Y; Wu S; Xia K; Xu C; Ma H; Zheng J; Luo L; Zhu F; He S; Zhang X
Eur J Med Chem; 2020 Nov; 205():112537. PubMed ID: 32768738
[TBL] [Abstract][Full Text] [Related]
7. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor.
Knight JC; Hallett AJ; Brancale A; Paisey SJ; Clarkson RW; Edwards PG
Chembiochem; 2011 Nov; 12(17):2692-8. PubMed ID: 21998043
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity.
Hesselgesser J; Liang M; Hoxie J; Greenberg M; Brass LF; Orsini MJ; Taub D; Horuk R
J Immunol; 1998 Jan; 160(2):877-83. PubMed ID: 9551924
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.
Di Salvo J; Koch GE; Johnson KE; Blake AD; Daugherty BL; DeMartino JA; Sirotina-Meisher A; Liu Y; Springer MS; Cascieri MA; Sullivan KA
Eur J Pharmacol; 2000 Dec; 409(2):143-54. PubMed ID: 11104827
[TBL] [Abstract][Full Text] [Related]
11. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
12. i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.
Griffiths K; Dolezal O; Cao B; Nilsson SK; See HB; Pfleger KDG; Roche M; Gorry PR; Pow A; Viduka K; Lim K; Lu BGC; Chang DHC; Murray-Rust T; Kvansakul M; Perugini MA; Dogovski C; Doerflinger M; Zhang Y; Parisi K; Casey JL; Nuttall SD; Foley M
J Biol Chem; 2016 Jun; 291(24):12641-12657. PubMed ID: 27036939
[TBL] [Abstract][Full Text] [Related]
13. Functional mimetic of the G-protein coupled receptor CXCR4 on a soluble antibody scaffold.
Koksal AC; Pennini ME; Marelli M; Xiao X; Dall'Acqua WF
MAbs; 2019; 11(4):725-734. PubMed ID: 30900513
[TBL] [Abstract][Full Text] [Related]
14. Development of a NanoBRET-Based Sensitive Screening Method for CXCR4 Ligands.
Sakyiamah MM; Nomura W; Kobayakawa T; Tamamura H
Bioconjug Chem; 2019 May; 30(5):1442-1450. PubMed ID: 30973227
[TBL] [Abstract][Full Text] [Related]
15. Multivalency in CXCR4 chemokine receptor targeted iron oxide nanoparticles.
Baghdadi NE; Burke BP; Alresheedi T; Nigam S; Saeed A; Almutairi F; Domarkas J; Khan A; Archibald SJ
Dalton Trans; 2021 Feb; 50(5):1599-1603. PubMed ID: 33502425
[TBL] [Abstract][Full Text] [Related]
16. Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2.
Fischer T; Nagel F; Jacobs S; Stumm R; Schulz S
PLoS One; 2008; 3(12):e4069. PubMed ID: 19116653
[TBL] [Abstract][Full Text] [Related]
17. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
Khan A; Greenman J; Archibald SJ
Curr Med Chem; 2007; 14(21):2257-77. PubMed ID: 17896975
[TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines.
Lin Y; Li Z; Ma H; Wang Y; Wang X; Song S; Zhao L; Wu S; Tian S; Fu C; Luo L; Zhu F; He S; Zheng J; Zhang X
ChemMedChem; 2020 Jul; 15(13):1150-1162. PubMed ID: 32391652
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel 2-(1H-indol-1-yl)-benzohydrazides CXCR4 ligands impairing breast cancer growth and motility.
Grande F; Barone I; Aiello F; Brancale A; Cancellieri M; Badolato M; Chemi F; Giordano C; Vircillo V; Bonofiglio D; Garofalo A; Andò S; Catalano S
Future Med Chem; 2016; 8(2):93-106. PubMed ID: 26807787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
